Aggrecan is a member of the chondroitin sulphate (CS) proteoglycan family, which also includes versican\PG-M, neurocan and brevican. Members of this family exhibit structural similarity : a G1 domain at the N-terminus and a G3 domain at the C-terminus, with a central sequence for modification by CS chains. A unique feature of aggrecan is the insertion of three additional domains, an inter-globular domain (IGD), a G2 domain and a keratan sulphate (KS) domain (sequence modified by KS chains), between the G1 domain and the CS domain (sequence modified by CS chains). The G1 and G3 domains have been implicated in product secretion, but G2, although structurally similar to the tandem repeats of G1, performs an unknown function. To define the functions of each aggrecan domain in product processing, we cloned and expressed these domains in various combinations in COS-7 cells. The results indicated that
INTRODUCTION
The proteoglycans are a family of glycoconjugates with a central core protein to which glycosaminoglycan (GAG) side chain(s) are covalently linked post-translationally [1] . The majority of the functions of proteoglycans are mediated by these GAG chains [2, 3] , which are polymers of repeated dissacharide units consisting of a uronic acid and a hexosamine. Biosynthesis of all GAGs, except hyaluronic acid, is initiated from a core protein. GAGs are O-linked to serine residues through a trisaccharide linkage sequence at their reducing ends : serinexylose-galactose-galactose. These GAG chains are acidic molecules, and they participate in a wide variety of binding interactions with other matrix macromolecules, cations and water [4, 5] . They can concentrate secretory products surrounding cells, and sequester a variety of extracellular proteins at cell surfaces. In cartilage, the matrix molecules that make up the extracellular matrix (ECM) include proteoglycans, hyaluronic acid, type II collagen, glycoproteins and various mixtures of elastic fibres. Aggrecan is the major structural proteoglycan in cartilage and is responsible for cartilage's resilience and load-bearing properties. Loss of aggrecan is a major feature of cartilage degradation associated with arthritis [6, 7] .
The core protein of aggrecan is composed of three globular domains (G1, G2 and G3), with one inter-globular domain (IGD) linking G1 and G2, and two exons for keratan sulphate (KS) chain attachment (KS domain) and for chondroitin sulphate (CS) chain attachment (CS domain) situated between G2 and G3. Attachment of these GAG chains occurs on the serine of serine-glycine dipeptide sequence present in this region, and one molecule of aggrecan can contain up to 100 CS chains, Abbreviations used : CS, chondroitin sulphate ; CS domain, sequence modified by CS chains ; DMEM, Dulbecco's modified Eagle's medium ; ECM, extracellular matrix ; FBS, fetal bovine serum ; GAG, glycosaminoglycan ; IGD, inter-globular domain ; KS, keratan sulphate ; KS domain, sequence modified by KS chains ; LB, Luria broth. 1 To whom correspondence should be addressed, at Sunnybrook & Women's College Health Sciences Centre (e-mail Burton.Yang!swchsc.on.ca).
the G3 domain enhanced product secretion, alone or in combination with the KS or CS domain, and promoted glycosaminoglycan (GAG) chain attachment. Constructs containing the G1 domain were not secreted. Addition of a CS domain sequence to G1 reduced this inhibition, but GAG chain attachment was still decreased. The potential GAG chain attachment site in the IGD was occupied by GAGs, and IGD product was secreted efficiently. The KS domain was modified by GAG chains and secreted. Finally, the G2 domain was expressed but not secreted, and inhibited secretion of the IGD when expressed as an IGD-G2 combination.
Key words : chondroitin sulphate, G1 domain, G2 domain, G3 domain, glycosaminoglycan, keratan sulphate.
30 KS chains and many O-and N-linked oligosaccharides [1] . The G1 domain comprises the N-terminus of the core protein.
This domain has the same structural motifs as link protein [8] . The G2 domain is homologous to the tandem repeats found in G1 and link protein. The G3 domain, which makes up the C-terminus of the core protein, is composed of alternatively spliced epidermal growth factor-like domains, a carbohydrate recognition domain, a complement-binding-protein-like domain and a short tail [9, 10] . Recent studies indicated that the G1 domain is poorly secreted, and that the G3 domain plays a role in the secretion of recombinant products [11] . However, the effects of the other domains on product secretion are not known. Given that there is up to 62.1 % identity between G1 and G2 tandem repeat motifs [2] , we reasoned that G2 might also play a role in product secretion. To test this, we have performed a comprehensive study of the role of the six domains of aggrecan in product processing using recombination and gene expression techniques. Our results indicated that the promotion of product secretion by G3 was inhibited by G1 and G2. This inhibition was overcome in the presence of G3 and the CS domain (i.e. sequence modified by CS chains), since G3 stimulated GAG chain attachment to this domain, and the GAG-modified product was effectively secreted. The IGD was modified by GAG chains, and the product was also well secreted.
EXPERIMENTAL Materials
Reverse transcription-PCR mRNA amplification kit, Taq DNA polymerase, T4 DNA ligase and restriction endonucleases were G1N  5h AAA CTC GAG CTG GGA AGC TCC CTG AAC 3h  Xho I  G1C  5h AAA CGG GAT CCC ATC ACC ACT GTA ACA GAT GGC ATC GTA 3h  Bam HI  G1C  5h AAA GTC GAC ATC ACC ACT GTA ACA GAT 3h  Sal I  G1C  5h AAA GCA TGC ATC ACC ACT GTA ACA GAT 3h  Sph I  IGDN  5h AAA CTC GAG GAC TTC GAG GCT CTG GTC CCA 3h  Xho I  IGDR  5h AAA TCT AGA GGG GGA AAT GGG CTG 3h  Xba I  G2MF  5h AAA GCA TGC GTA GGA GAC AAA GAG AGC 3h  Sph I  G2MR  5h AAA GCA TGC GCT GCG GGG ATT CAC AAT 3h  Sph I  G2F  5h AAA CTC GAG GGT GTG GTG TTC CAC TAC 3h  Xho I  G2R  5h AAA TCT AGA TCT GAA GCA GAA AGC GTG 3h  Xba I  KSN  5h AAA GTC GAC GCT CTG CCA TCC GTA GTG 
Strategy for cloning and construction of recombinant genes
In order to generate expression constructs containing various regions of mature aggrecan, we used the following schemes, using chicken cDNA (synthesized from chicken mRNA) as template and two primer sets, IGDNXhoI\G2MRSphI and KSCXbaI\G2MFSphI in PCR reactions. Sequences for all primers used in this study are shown in Table 1 according to the published sequence [12, 13] . IGD-G2 (the N-terminal half of G2) was amplified using the first primer set, and G2-KS (the Cterminal half of G2) was amplified using the second primer set in PCR. These PCR products were agarose-gel-purified and doubly digested with their respective restriction enzymes. The restricted PCR fragments were further gel-purified and ligated into XhoI\ XbaI-restricted mammalian expression vector pcDNA3 carrying link protein leading peptide, which is recognized by the monoclonal antibody 4B6. The cDNA of link protein leading peptide was synthesized using LPNEcoRI and LPCBamHI as primers and the link protein cDNA as template in a PCR reaction. The PCR products were then gel-purified and doubly digested and ligated into EcoRI\BamHI-restricted pcDNA3. The ligation mixture was then used as template to PCR-amplify the construct IGD-G2-KS using the primers LPNEcoRI\KSCXbaI utilizing the Invitrogen Unidirectional TA Cloning Kit. A 2 µl portion of the ligation mix was used to transform E. coli TOP10Fh cells, as described by the manufacturer. The transformation mixture was plated on a Luria broth (LB) plate containing 50 mg\ml kanamycin. The resultant construct, IGD-G2-KS, was confirmed using restriction digestion and sequencing. IGD-G2-KS was then used as template to amplify IGD, G2, KS domain and IGD-G2 fragments using the following primer sets : IGDNXhoI\IGDRXbaI for IGD, G2FXhoI\ G2RXbaI for G2, KSNSal I\KSCXbaI for the KS domain and IGDNXhoI\G2RXbaI for IGD-G2. The PCR products were gel-purified and doubly digested overnight at 37 mC with the respective enzymes. The digested fragments were further gelpurified and used in ligation reactions (16 mC overnight) with XhoI\XbaI-restricted pcDNA3 harbouring a 5h LP60 sequence. In order to increase the cloning efficiency, the ligation reaction mixtures were used further as templates to amplify IGD, G2, the KS domain and IGD-G2 using the following primer sets : LPNEcoRI\IGDRXbaI for IGD, LPNEcoRI\G2RXbaI for G2, LPNEcoRI\KSCXbaI for KS and LPNEcoRI\G2RXbaI for IGD-G2. The amplified products were cloned using an Invitrogen Unidirectional TA Cloning Kit.
To generate the expression construct G1-KS, we first PCR-amplified the G1 fragment from a recombinant construct containing G1, which was cloned and expressed by us previously [14] [15] [16] , using the primer set LPNEcoRI\AG1CSal I. The KS domain was also amplified, using the primers KSNSal I\KSCXbaI, and with IGD-G2-KS as a template. This PCR product was gel-purified and doubly digested overnight with Sal I and XbaI. The digested materials were again gelpurified and ligated into EcoRI\XbaI-digested pcDNA3. The ligation mixture was used further as template to PCR-amplify the G1-KS fragment using the primer set LPNEcoRI\KSCXbaI and cloned utilizing the Invitrogen Unidirectional TA Cloning Kit. The identity of the resultant recombinant DNA was confirmed by restriction digests and sequencing.
To generate G3-KS, we PCR-amplified the G3 moiety, which was originally cloned by Stirpe et al. [17] , from the template G3 cDNA in pcDNA3 using the primers LPNEcoRI\G3CXhoI. The KS domain was also PCR-amplified from the IGD-KS construct using the primers KSNSal I\KSCSphI. The PCR products were gel purified and doubly digested with EcoRI and XhoI or Sal I and SphI respectively. The digested products were purified and eventually ligated into EcoRI\SphI-restricted pcDNA1. The ligation mixture was used in the transformation of E. coli strain MC1061, and the transformed cells were plated on to LB plates containing 50 µg\ml ampicillin and 10 µg\ml tetracycline.
The construction of expression plasmid G1-G2 was accomplished as follows. The G1 moiety was PCR-amplified from the G1 construct using the primers LPNEcoRI\G1CSal I and doubly digested with EcoRI and Sal I. The G2 moiety was isolated from the XhoI\XbaI-digested G2 construct. These fragments were ligated into the EcoRI\XbaI-digested pcDNA3. The ligation mixture was used to PCR-amplify the whole fragment, G1-G2, using the primer set LPNEcoRI\G2RXbaI. The PCR products were cloned directly into pCR3.1.
To generate the G1-G3 construct, the primers LPNEcoRI\ G1CSal I were used to amplify the G1 fragment. G1 was ligated (after double digestion with EcoRI and Sal I and gel purification) into the EcoRI\XhoI-digested G3 construct (in pcDNA3). The identity of resultant recombinant, G1-G3, was further confirmed by restriction digestion and sequencing.
To construct another set of recombinant DNA fragments, i.e. the CS domain, G1-CS and CS-G3, our strategy was to PCRamplify the following DNA fragments : link protein leading sequence, G1, CS domain and G3. The DNA fragments were then ligated together in various combinations in pcDNA3, and their identities were confirmed by restriction digestion and sequencing. Briefly, an EcoRI site and a BamHI site were created at the 5h and 3h ends of link protein that was cloned previously [8] . After using the primer set CSNBamHI\CSCXbaI and the chicken genomic DNA as template, CS domain PCR products were purified and digested with BamHI and XbaI. The digested link protein leading sequence and CS fragment were ligated into EcoRI\XbaI-digested pcDNA3. After an overnight incubation of the ligation mixture at 16 mC, E. coli strain TOP10Fh was transformed with the mixture.
In order to generate CS-G3, we PCR-amplified the G3 domain using the primer set G3NXhoI\G3CXbaI, and amplified the CS fragment from the CS construct using primers LPNEcoRI\ CSCXhoI. The PCR fragments were digested and ligated into EcoRI\XbaI-digested pcDNA3. The ligation mixture was used in the transformation of TOP10Fh cells.
The G1-CS construct was generated in the same manner. Using the primer sets LPNEcoRI\G1CSal I and CSNXhoI\ CSCXbaI, we amplified the G1 and CS fragments respectively. These PCR products were digested and ligated into EcoRI\XbaI-restricted pcDNA3, followed by transformation of E. coli strain TOP10Fh.
DNA amplification, purification, ligation and transformation
DNA was amplified in a PCR reaction using pairs of appropriate primers. The reaction mixture (total final volume of 100 µl) contained 200 µM dNTPs, 0.2 µg of each primer, 50 ng of template DNA, 2 units of Taq DNA polymerase and Mgcontaining buffer (Boehringer Mannheim). The reactions were carried out at 94 mC for 5 min for one cycle, then for 25 cycles at 94 mC for 60 s, 55 mC for 60 s and 72 mC for 60-120 s (depending on the size of DNA amplified), with a final extension at 72 mC for 10 min.
The DNA products from PCR reactions were purified using a Prep-A-Gene DNA purification kit, following the manufacturer's instructions. The purified DNA was doubly digested with two appropriate restriction endonucleases, purified and eluted into 40 µl of water. The DNA was then ligated into the appropriate plasmid (pcDNA1, pcDNA3 or pCR3.1), which had been linearized with appropriate restriction enzymes. A ligation mixture typically contained 1 µl of ligation buffer, 1 µl of DNA ligase, 3 µl of plasmid vector (50 ng) and 5 µl of insert (150 ng). The ligation reaction was carried out at 14 mC (for pCR3.1) or 16 mC (for pcDNA1 and pcDNA3) overnight. A 2 µl portion of the ligation mixture were used to transform competent E. coli strain MC1061 (for pcDNA1 vector backbone) or TOP10Fh (for pcDNA3 and pCR3.1 vector backbones).
To prepare electro-competent bacteria, E. coli cells were grown in 1 litre of LB until the density (D &*! ) reached 0.8. The cells were pelleted for 10 min at 10 000 g, washed twice with water, resuspended in 4 ml of water containing 10 % (v\v) glycerol, divided into aliquots (100 µl each) and stored at k70 mC. In a transformation reaction, 2-5 µl of DNA ligation mixture was combined with 100 µl of competent bacteria in a 0.2 cm cuvette and electroporated at 2.5 kV in a Bio-Rad electroporator. The settings for the gene pulser and capacitance extender were : capacitance set at 25 µF, capacitance extender set at 960 µF and resistance set at 200 Ω. The mixture was transferred to 0.5 ml of SOC medium [18] , agitated at 230 rev.\min for 45 min at 37 mC and spread on to regular LB agar plates containing appropriate antibiotics and cultured at 37 mC overnight.
Expression of recombinant constructs in COS cells
COS-7 cells were transiently transfected with recombinant constructs using Lipofectin (GIBCO) according to the manufacturer's instructions. Briefly, the cultured COS-7 cells were seeded on to a six-well plate (1.5i10& cells\well). The cells were allowed to attach and grow overnight in DMEM supplemented with 5 % (v\v) FBS. The following day the COS-7 cells had reached 70 % confluence, at which time they were ready for transfection. Lipofectin (10 µl) was incubated with plasmid DNA (5 µg) for 15 min in 200 µl of DMEM, followed by addition of 800 µl of DMEM. During the incubation, the COS-7 cell culture was rinsed with 2 ml of DMEM. The Lipofectin\DNA mixture was applied to the rinsed cultures and incubated for 10 h. Then the DNA\Lipofectin mixture was replaced with 1 ml of DMEM supplemented with 5 % (v\v) FBS. At 3 days after transfection, growth medium and cell lysate were harvested separately, and samples were frozen until analysis. For time course analysis of product expression, transfection of COS-7 cells with G1, G2 or G3 constructs was carried out as above. Culture medium and cell lysate were harvested 1, 2 and 3 days after the addition to the cultures of DMEM supplemented with 5 % (v\v) FBS, and expression of these constructs and secretion of the products was analysed by Western blotting.
Western blot assays
Cell lysate and culture medium were subjected to SDS\PAGE, as described previously [19, 20] . Proteins separated by SDS\ PAGE were transblotted on to a nitrocellulose membrane (Bio- Rad) in 1iTG buffer (Amresco) containing 20 % (v\v) methanol at 60 V for 2 h in a cold-room. The membrane was blocked in TBST (10 mM Tris\HCl, pH 8.0, 150 mM NaCl, 0.05 % Tween 20) containing 10 % non-fat dry milk powder (TBSTM) for 1 h at room temperature, and then incubated at 4 mC overnight with monoclonal antibody 4B6 diluted in TBSTM. The membranes were washed with TBST (3i30 min) and then incubated for 1 h with horseradish peroxidase-conjugated goat anti-mouse antibody diluted (1 : 1000) in TBSTM. After washing as above, the bound antibody was visualized by chemiluminescence (ECL kit ; Amersham).
Treatment with chondroitinase ABC
Protein A beads (50 µl of gel slurry) were incubated with an excess amount of 4B6 antibody at room temperature for 2 h. The unbound antibody was recovered, and the gel beads were washed extensively with PBS three times. Culture medium from COS-7 cells transfected with mini-aggrecan construct was mixed with 2iPBS in a 1 : 1 (v\v) ratio, followed by incubation with the antibody-bound gel beads at 4 mC overnight. The gel beads were washed extensively and resuspended in 20 µl of 1iPBS. Chondroitinase ABC (0.25 unit) was added to digested GAG chains at 37 mC for 2 h. The digested product was recovered with 1i protein loading dye, and analysed on Western blot probed with antibody 4B6 as above.
Densitometer analysis
Relative protein concentrations were estimated using a densitometer (Molecular Dynamics) to scan the densities of the signals after Western blotting. The relative intensity of each band after Western blot development is shown below each blot (i10$).
RESULTS

Expression of recombinant constructs
To study the roles of each aggrecan domain in product biosynthesis, GAG chain modification and product secretion, we generated a number of recombinant constructs carrying different domains of aggrecan : G1, G2, G3, IGD, KS, CS, G1-G2, G1-G3, G1-CS, G1-KS, IGD-G2, G1CSD, miniaggrecan, CS-G3 and G3-KS. The structures of these constructs are shown in detail in Figure 1 . To allow direct comparisons of expression and secretion, each construct contained the same leading peptide for product targeting. This leading peptide, originally obtained from link protein, contains an epitope recognized by the monoclonal antibody 4B6 [21] . The mammalian expression vectors pcDNA1, pcDNA3 and pCR3.1 are driven by a CMV (cytomegalovirus) promoter. These constructs were used in transfection of COS-7 cells using Lipofectin, as described in the Experimental section. The growth medium and cell lysate were harvested and analysed on Western blots probed with antibody 4B6 and visualized with a ECL kit (Amersham) according to the manufacturer's instructions.
G3 enhances GAG modification of KS and CS domains, and facilitates product secretion
It has been reported in studies using CHO cells that an aggrecan G3 construct was well synthesized and secreted into the culture Six major domains of aggrecan
Figure 2 G3 enhances KS domain synthesis and secretion
COS-7 cells were transiently transfected with the recombinant constructs G3 (A), KS (B) and G3-KS (C). The cultures were maintained in DMEM complemented with 5 % (v/v) FBS at 37 mC in an incubator for 3 days. Cell lysate and culture media were subjected to SDS/PAGE (1, 2, 5 and 10 µl per well) in a 10 % (w/v) polyacrylamide gel. The separated proteins were then transblotted on to a nitrocellulose membrane and probed with the monoclonal antibody 4B6. Products of G3 (" 48 kDa) were synthesized and secreted into the culture medium. Products of KS (" 30-35 kDa) were weakly synthesized, secreted into the culture medium and modified by GAGs, resulting in smear bands in the gel. Products of G3-KS (" 50-70 kDa) were heavily modified by GAGs, resulting in strong smear bands in the gel. The relative densities of each band after Western blot development are shown below each gel (i10 3 ). Due to a limiting sensitivity and saturation effect of the film, this reading does not correlate proportionally to increases in volume loaded on to each well. medium, while a G1 construct was poorly synthesized and weakly secreted into the culture medium [22] . Therefore, in our study of the role of this and other aggrecan domains in product biosynthesis, modification by GAG chains and secretion, we first confirmed that an aggrecan G3 construct was well synthesized and secreted into the culture medium when expressed in COS-7 cells (Figure 2A ). The KS construct was expressed in the same way ; it was weakly synthesized and secreted into the culture medium, and weakly modified by GAG chains ( Figure 2B ). When the KS domain was linked to the G3 construct, the resulting G3-KS construct was well synthesized and strongly modified by GAG chains. A high proportion of products appeared in the culture medium ( Figure 2C) .
We further tested the role of the G3 domain in GAG modification of the CS domain sequence. A construct containing 
Figure 4 G1 inhibits G3 secretion
Cells were transiently transfected with the recombinant construct G1-G3. Cell lysate and culture medium were analysed on Western blots (1, 2, 5 and 10 µl per well) probed with antibody 4B6. The products (" 72 kDa) were well synthesized, but poorly secreted into the culture medium. The relative densities of each band after Western blot development are shown below each gel (i10 3 ).
the G3 domain and a fragment of the CS domain (nucleotides 3838-5580, equivalent to 51 % of the entire CS domain of aggrecan [12, 13] ) was expressed in COS-7 cells. The CS construct containing the leading peptide and the CS fragment was used as a control. The experiment indicated weak synthesis and secretion of the CS construct ( Figure 3A) , while the CS-G3 construct was well synthesized and secreted ( Figure 3B ). When a G1-G3 construct was expressed in the same way, the construct produced a noticeable amount of protein in the cell lysate ( Figure 4) . Surprisingly, little was observed in the medium, suggesting that the G1 domain exerts a strong inhibitory effect on secretion.
The decrease in GAG modification and inhibition of product secretion caused by G1 is partially abolished by the CS domain, and enhanced by G3
To test further the hypothesis concerning the effect of G1 on secretion, we performed a product secretion assay using a G1 construct. The assay revealed that the G1 products were well
Figure 5 G1 inhibits KS domain secretion
Cells were transiently transfected with the G1 and G1-KS constructs. Cell lysate (L1 ; 1 µl) and culture medium (M10 ; 10 µl) were analysed on a Western blot probed with antibody 4B6. Products of the G1 construct (55 kDa) were synthesized, but not secreted into the culture medium (A). Products of G1-KS were well produced (detected in the cell lysate) but poorly modified by GAG chains, and could not be detected in the culture medium (B). The relative densities of each band after Western blot development are shown below each gel (i10 3 ).
synthesized, but that the product was barely detected in the culture medium ( Figure 5A ). We then tested the effect of the G1 domain on GAG modification of the KS sequence. COS-7 cells were transiently transfected with the construct G1-KS. Cell lysate and culture medium were harvested and analysed on a Western blot probed with antibody 4B6. The presence of G1 inhibited the addition of GAG chains to the G1-KS core protein, and completely prevented secretion of the G1-KS product ( Figure 5B ). Further, we tested whether G1 could inhibit GAG modification of the CS domain sequence and inhibit product secretion. To do this, we expressed a G1-CS construct in COS-7 cells. The G1 domain only partially inhibited GAG modification of the CS domain sequence and partially decreased product secretion as compared with the control construct CS ( Figure 6A) . In other words, the inhibitory effect of G1 on product secretion was partially overcome by the presence of the CS domain sequence. The G1 domain was then linked to a small fragment of the CS domain sequence (CSD) in the presence or the absence of the G3 domain. The resulting constructs, G1-CSD and G1-CSD-G3, were expressed. The core protein of G1-CSD was not modified by GAG chains, and the product was not secreted (Figure 6B ), while the core protein of G1-CSD-G3 was modified by GAG chains and the products were well secreted ( Figure 6C) . Treatment of the mini-aggrecan product with chondroitinase ABC resulted in a core protein with a molecular mass of 130 kDa.
G2 inhibits product secretion
Since G1 has an inhibitory effect on product secretion, and since G2 exhibits extensive homology with the tandem repeats of G1, we reasoned that G2 might also inhibit product secretion. The G2 construct was expressed in COS-7 cells, and cell lysate and culture medium were analysed on Western blots probed with antibody 4B6. The product was poorly synthesized and was not observed in the culture medium ( Figure 7A) . A time course study of G2 expression ( Figure 7B) , with the controls of G1 ( Figure  7C ) and G3 ( Figure 7D) , indicated that the products of G1 and G2 accumulated in the cell lysate and reached equilibrium after 2 days of transfection, while the product of G3 reached equilibrium 1 day later. Notably, when the G2 domain was linked to the G1 construct, producing G1-G2, G2 did not inhibit the biosynthesis of G1. As a result, the G1-G2 products were well
Figure 6 Inhibition of secretion by G1 is overcome by the CS domain and enhanced by G3
Cells were transiently transfected with constructs G1-CS (A), G1-CSD (B) (where CSD is a small fragment of the CS domain sequence) and mini-aggrecan (C) (G1-CSD-G3). Cell lysate and culture medium were analysed on Western blots probed with antibody 4B6. For comparison, the lysate (20 µl) and culture medium (20 µl) of cells containing products of construct CS were loaded as controls in (A). The products of G1-CS (" 180-200 kDa) were well synthesized, weakly modified by GAG chains and weakly secreted into the culture medium as compared with the products of CS. The products of G1-CSD were well synthesized, but barely detected in the culture medium. The products of mini-aggrecan (G1-CSD-G3) were well synthesized, modified by GAG chains and secreted into the medium. The product of mini-aggrecan in the culture medium was also purified using 4B6 and treated with chondroitinase ABC, and the product with (ABC) or without (control) chondroitinase ABC treatment was analysed by Western blotting. The core protein of the mini-aggrecan was detected with a molecular mass of 130 kDa. The relative densities of each band after Western blot development are shown below each gel (i10 3 ).
produced, but, as expected, they were not secreted into the culture medium ( Figure 7E ). Finally, we investigated the role of the IGD in product biosynthesis and secretion. COS-7 cells were transiently transfected with the IGD construct. Analysis of the cell lysate and culture medium indicated not only that the IGD products were well produced and secreted into the culture medium, but also that the core proteins were heavily modified by GAG chains ( Figure 7F) . A search of the sequence of the IGD revealed a unique pair of Ser-Gly residues, a potential sugar attachment site, coded by nucleotides 1055-1060. This suggests that this site is modified by GAG chain attachment. In light of the proximity of IGD to G2 (G2 is directly C-terminal to IGD), we chose to investigate the potential effect of the G2 domain on IGD biosynthesis, modification by GAG chains and product secretion.
Figure 7 Effects of the G2 domain on GAG chain attachment and product secretion
Cells were transiently transfected with the constructs G2, G1, G3, G1-G2, IGD and IGD-G2, as described in the legend to Figure 2 . Cell lysate (L1 and L10 ; 1 and 10 µl respectively) and culture medium (M10 ; 10 µl) were analysed on Western blots and probed with antibody 4B6. Products of G2 (" 22 kDa) were synthesized, but were not secreted into the culture medium (A). The time course of the expression of G2 was also analysed (B), while the expression of G1 (C) and G3 (D) served as controls for the time course study (10 µl samples). Products of G1-G2 were well synthesized, but were not secreted into the culture medium (E). Products of IGD were synthesized and modified by GAG chains, resulting in smear bands in the gel, and secreted into the culture medium. The sizes of protein in the lysate were approx. 40-45 kDa, while those in the culture medium were approx. 45-65 kDa (F). The products of IGD-G2 were well synthesized and modified by GAG chains, but they were not secreted (G). The relative densities of each band after Western blot development are shown below each gel (i10 3 ).
An IGD-G2 construct was generated and expressed as described above. Western blot analysis indicated that the G2 domain completely prevented the secretion of IGD ( Figure 7G ). However, G2 did not inhibit biosynthesis, and seemed to reduce GAG chain modification of the IGD-G2 core protein only.
DISCUSSION
Our work reported here represents the first comprehensive study of the role of each aggrecan domain in product processing. We have demonstrated that the G1 and G2 domains reduce modification by GAG chains of the core proteins and inhibit product secretion. There are also two components that stimulate product secretion : the G3 domain and the GAG-chainmodified sequences (CS domain, KS domain and IGD). The G3 domain not only stimulates product secretion, but also promotes the attachment of GAG chains. The KS and CS domain sequences are poorly modified by GAG chains in the absence of the G3 domain. The G3 domain, however, is not able to stimulate the secretion of G1 sufficiently. For instance, the products of G1-G3 were barely detected in the culture medium. Only in the presence of a fragment of the CS domain sequence (e.g. the CSD fragment in the G1-CSD-G3 construct), where the G3 domain facilitates GAG chain attachment to the CS fragment, resulting in the presence of two positive components for product secretion, can the inhibitory effects of G1 be abolished. The fact that the endogenous aggrecan, which contains two components (G1 and G2 domains) for the inhibition of product secretion and two components (G3 domain and modified GAG chains) for product secretion, is secreted into the ECM implies that the G3 and CS domains, by working together, play a predominant role in product secretion. In our experience, we have never observed secretion of the unmodified core proteins of mini-aggrecan, mini-versican, aggrecan G1-CS construct or versican G1-CS construct. These results indicate that GAG chain attachment is imperative for secretion of these proteoglycans.
Further support for this is provided by our observation that the inhibition of product secretion by G1 was overcome by a larger CS domain sequence (G1-CS), but not by a smaller CS domain sequence (G1-CSD). It has been reported that the enhancement by the G3 domain of product secretion occurs through its interaction with HSP25 (heat-shock protein of 25 kDa) [22] . Each protein module also enhances product secretion [23, 24] . The mechanism of our observation that modification by GAG chains stimulates product secretion awaits future investigation. An interesting question then arises : why are chondrocytes programmed to produce two components for inhibition of product secretion ? Our findings that G3, in the absence of a CS domain fragment, was not able to stimulate G1 secretion in the construct G1-G3, and that the G1-CS core protein was weakly modified by GAG chains and the GAG-modified products were secreted, seem to indicate that the cells are programmed to produce ' perfect ' aggrecan molecules. Aggrecan core protein cannot be mistakenly secreted into the matrix following mRNA translation, as the G1 and G2 domains will inhibit its secretion. Only after the aggrecan core protein is correctly modified by GAG chains could the proteoglycan be secreted. This programming is very important for cartilage development and maintenance, since the GAG chains play important roles in retaining water and negative charges and in producing a loadbearing cartilage.
The presence of the G2 domain may be essential, since cells have to completely block secretion of any imperfect aggrecan. Indeed, without the G2 domain, the G1-CS core protein was weakly modified and the product was weakly secreted. One may imagine that the products of such under-modification by GAG chains would be harmful in cartilage development and maintenance. This hypothesis is supported not only by our experimental results, but also by previous studies on other members of this CS proteoglycan family, which indicated that these proteoglycans are essential for tissue development and growth [25] [26] [27] [28] . Aggrecan contains a G2 domain, and its core protein is heavily modified by GAG chains, while other family members (i.e. versican, neurocan and brevican) do not contain a G2 domain and their core proteins are not heavily modified by GAG chains. This should not lead to an incorrect assumption that G2 enhances modification by GAG chains. It is the G3 domain, and not the G2 domain, that promotes GAG chain attachment. The G2 domain not only inhibits product secretion, but also reduces modification by GAG chains. Its effect on product secretion seems to be predominant, in order to inhibit secretion of insufficiently modified aggrecan. As a result, only those molecules sufficiently modified by GAG chains are secreted into the ECM. The G3 domain, on the other hand, enhances GAG chain attachment and stimulates product secretion. The importance of the G3 domain is seen in nanomelia, a fatal genetic disease of the chicken. Nanomelic aggrecan contains a premature stop codon at the 3h end of the CS domain sequence (5h to the G3 domain), and the mutant aggrecan core protein is neither modified by GAG chains nor secreted into the ECM [29, 30] . Another fatal genetic disease that demonstrates the importance of the CS and G3 domains is the cartilage deficiency in mice whose aggrecan contains a 7 bp deletion in exon 5 (tandem repeat 1 motif of the G1 domain). As a result, the truncated aggrecan can no longer be secreted into the matrix [26, 31] .
It has long been known that the G2 domain is structurally similar to the tandem repeats of the G1 domain. While the G1 domain binds to link protein via the IgG-like motif and binds hyaluronan via the tandem repeats, forming ternary complexes to maintain a stable matrix network in cartilage, the G2 domain does not bind to hyaluronan [32] and, so far, no molecule has been found to interact with G2. The function of the G2 domain remains unknown. Our report on the role of the G2 domain in aggrecan processing has, for the first time, shed some light on the biology of this domain.
Another novel finding in our studies is the modification of the IGD by GAG chains. There is only one potential site on the IGD for GAG chain attachment. Our observation that the IGD construct was synthesized and modified by GAG chains, and that the product was secreted into the culture medium, implies that the potential site is actually modified by GAG chains in the COS-7 cell line. This could only be achieved by using a small recombinant construct. In a large construct, which may contain many sites for GAG chain attachment, one cannot distinguish the presence or absence of one particular GAG chain. It is not yet known whether this site is modified by GAG chains in endogenous aggrecan.
Thus, given the diversity of effects exerted by aggrecan domains on product processing, it is likely that each domain is involved in the processing and secretion of the mature aggrecan product. In the model we propose, the G1 and G2 domains reduce modification by GAG chains, which is overcome by the G3 domain. G3, through promotion of GAG chain attachment, overcomes the inhibitory effects of G1 and G2 on product secretion. The attachment of GAG chains to the IGD, the KS domain and the CS domain, which allows aggrecan to generate stable matrix meshwork, is also a prerequisite for aggrecan secretion.
